Stock Screener App

무료 -

Drug Manufacturers - General

42.52

1.93% -0.84

브리스톨 마이어스 스퀴브 (BMY)

개요 뉴스 가격 이력 옵션 체인 Financials BMY 왜 하락? 토론 예측 주식 분할 배당 이력

Bristol-Myers Squibb Co. 주식(BMY)의 최신 뉴스

Biopharma Layoff Tracker 2024: Exscientia, BIO, Erasca and More Cut Staff - BioSpace

1 Stock I Wouldn't Touch With a 10-Foot Pole

The Motley Fool

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration ... - PR Newswire

Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous ... - Business Wire

Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch

3 Cheap and Dependable Dividend-Growth Stocks to Buy - Morningstar

November 15th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq

Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 79% - Yahoo Finance UK

Yahoo Finance UK

Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion - MSN

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers

Zacks Investment Research

BMS reports four-year data from psoriasis treatment extension trial - Clinical Trials Arena

Clinical Trials Arena

BMS reports four-year data from psoriasis treatment extension trial - Clinical Trials Arena

Clinical Trials Arena

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch

TD Cowen maintains $67 target on Bristol-Myers Squibb By Investing.com - Investing.com

Walmart Earnings & the State of the Consumer

Zacks Investment Research

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

Zacks Investment Research

FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated F - Benzinga

Bristol Myers Squibb Enters Oversold Territory (BMY) - Nasdaq

BMY: 3 Pharma Stocks Primed for May Investment Opportunities - StockNews.com

FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma - Pharmaceutical Technology

Pharmaceutical Technology

Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion

Zacks Investment Research

FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma - Pharmaceutical Technology

Pharmaceutical Technology

Our company - Worldwide locations - Bristol Myers Squibb

Bristol Myers Squibb

Biopharma Layoff Tracker 2024: Bolt, Tenaya, BioMarin and More Cut Staff - BioSpace

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed ... - Financial Times

Financial Times

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch

Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal - Yahoo Movies Canada

Yahoo Movies Canada

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Pfizer: Best Trading Momentum Since 2021 And 6% Yield

Biopharma Layoff Tracker 2024: Bolt, Tenaya, BioMarin and More Cut Staff - BioSpace

Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch

Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda ... - Chronicle-Tribune

Chronicle-Tribune

Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda ... - Business Wire

Drug Tech Co. Hires J&J Atty As Chief Strategy Officer - Law360

Why Bristol Myers Squibb turned to Ted Danson to promote a plaque psoriasis treatment - PR Week

Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch

Why Bristol Myers Squibb turned to Ted Danson to promote a plaque psoriasis treatment - PR Week

BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC - Pharmaceutical Technology

Pharmaceutical Technology

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study - Yahoo Finance

Bristol Myers fails to beat AstraZeneca in stage 3 lung cancer - FiercePharma

Bristol Myers fails to beat AstraZeneca in stage 3 lung cancer - FiercePharma

Bristol-Myers Squibb (NYSE:BMY) Stock Price Down 0% - Defense World

Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip

The Motley Fool

$44.61

0.03%

$48.83

0.82%

$28.47

0.21%

$313.24

0.44%

$102.90

0.07%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기